Why Cesium?


There are three different isotopes that can be used in brachytherapy: iodine-125, palladium-103, and Cesium-131. Dr. Brian Moran of the Chicago Prostate Center recently shared why Cesium-131 is his preferred isotope for treatment of prostate cancer. Here are his insights.

“I prefer the energy profile of Cesium-131, especially for my focal therapy patients. It is less prone to cold spots, when looking at it’s energy level profile.

“Cesium-131 has the most powerful energy of the three; it also has the shortest half life,” says Dr. Moran. “This is advantageous when you have a patient who may be concerned and ask ‘am I going to be radioactive for a long period of time?’

“It is comforting for some men to know the radiation will be leaving their body more quickly than say iodine, which has a 60 day half life or palladium, which has a half life of 17 days.”

If you or a loved one has recently been diagnosed with prostate cancer and want to know about all of your available treatment options as well as learn more about how Cesium-131 may improve patient outcomes email patienteducation@isoray.com.

Don’t miss us and come discover the Power of Blu™ at ASTRO 2019

Don’t miss us and come discover the Power of Blu™ at ASTRO 2019

At Isoray, we recognize the value of industry conferences, specifically when it comes to continuing your education, staying up-to-date with the latest research, and networking with industry colleagues. Our team is looking forward to once again having the opportunity to join the radiation oncologist community at the ASTRO Annual Meeting to discuss the most recent developments in cancer treatment. 

read more
ABS 2019: Growing Your Practice, Cesium Data & The Power of Blu

ABS 2019: Growing Your Practice, Cesium Data & The Power of Blu

Isoray was proud to be a part of yet another annual meeting for the American Brachytherapy Society (ABS) in Miami and, as we’ve had some time to process all of the stimulating conversations and unique opportunities that ABS always provides, we’d like to highlight some of our favorite moments and discussions from this year’s event. 

read more